Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 88

Sort by

Sort Order Select

Journal Articles

Abstract 5559: Exploratory analysis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) PIK3CA mutated (mut) advanced breast cancer (aBC) treated with taselisib (TAS) and/or fulvestrant (FUL) reveals increased CCNE2 expression with poor outcome to placebo (PBO) + FUL but not TAS + FUL in SANDPIPER

Radia M. Johnson, Bonnie Liu, Javier Cortés, Susan Dent, Nadia Harbeck, Ian E. Krop, William Jacot, Robert L. Yauch, Thomas J. Stout, Frauke Schimmoller, Steven Gendreau, Timothy R. Wilson

Cancer Res (2023) 83 (7_Supplement): 5559.

https://doi.org/10.1158/1538-7445.AM2023-5559

Published: 04 April 2023

View article titled, Abstract 5559: Exploratory analysis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) PIK3CA mutated (mut) advanced breast cancer (aBC) treated with taselisib (TAS) and/or fulvestrant (FUL) reveals increased CCNE2 expression with poor outcome to placebo (PBO) + FUL but not TAS + FUL in SANDPIPER

Journal Articles

Abstract P1-11-01: Trastuzumab deruxtecan vs treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04

Cancer Res (2023) 83 (5_Supplement): P1-11-01.

https://doi.org/10.1158/1538-7445.SABCS22-P1-11-01

Published: 01 March 2023

View article titled, Abstract P1-11-01: Trastuzumab deruxtecan vs treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04

Journal Articles

Abstract P1-02-01: Comparing the efficacy of aromatase inhibitors vs tamoxifen in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and trial-level meta-analysis

Wolfgang Janni, Michael Untch, Nadia Harbeck, Joseph Gilgorov, William Jacot, Stephen K. Chia, Jean-Francois Boileau, Sina Haftchenary, Rhea Gupta, Namita Mishra, Purnima Pathak, Giuseppe Curigliano

Cancer Res (2023) 83 (5_Supplement): P1-02-01.

https://doi.org/10.1158/1538-7445.SABCS22-P1-02-01

Published: 01 March 2023

View article titled, Abstract P1-02-01: Comparing the efficacy of aromatase inhibitors vs tamoxifen in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and trial-level meta-analysis

Journal Articles

Abstract OT2-16-02: Open-label, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer: DESTINY-Breast12

Nancy U. Lin, Eva Ciruelos, Guy Jerusalem, Volkmar Müller, Naoki Niikura, Giuseppe Viale, Emma Oscroft, Shawn Anand, Manoj Prahladan, Nadia Harbeck

Cancer Res (2023) 83 (5_Supplement): OT2-16-02.

https://doi.org/10.1158/1538-7445.SABCS22-OT2-16-02

Published: 01 March 2023

View article titled, Abstract OT2-16-02: Open-label, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer: DESTINY-Breast12

Journal Articles

Abstract OT2-03-02: lidERA Breast Cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy in patients with estrogen receptor+, HER2– early breast cancer

Peter Schmid, Charles E. Geyer Jr, Nadia Harbeck, Mothaffar Rimawi, Sara Hurvitz, Miguel Martín, Sherene Loi, Shigehira Saji, Kyung Hae Jung, Gustavo Werutsky, Daniil L. Stroyakovsky, Vanesa López-Valverde, Michael Davis, Tanja Badovinac Crnjevic, Pablo D. Perez-Moreno, Aditya Bardia

Cancer Res (2023) 83 (5_Supplement): OT2-03-02.

https://doi.org/10.1158/1538-7445.SABCS22-OT2-03-02

Published: 01 March 2023

View article titled, Abstract OT2-03-02: lidERA Breast Cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy in patients with estrogen receptor+, HER2– early breast cancer

Journal Articles

Abstract GS1-09: Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes

Cancer Res (2023) 83 (5_Supplement): GS1-09.

https://doi.org/10.1158/1538-7445.SABCS22-GS1-09

Published: 01 March 2023

View article titled, Abstract GS1-09: Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes

Journal Articles

Abstract HER2-18: HER2-18 Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04

Aleix Prat, Shanu Modi, Junji Tsurutani, David Cameron, Nadia Harbeck, Charo Garrido, Maha Karnoub, Ching Hsu, Wenquin Feng, Lotus Yung, Yibin Wang, Dhiraj Gambhire, Shirin K. Ford, Patrik Vitazka, Naoto T. Ueno

Cancer Res (2023) 83 (5_Supplement): HER2-18.

https://doi.org/10.1158/1538-7445.SABCS22-HER2-18

Published: 01 March 2023

View article titled, Abstract HER2-18: HER2-18 Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04

Journal Articles

Abstract TC1-3-1: Ki 67 Ki67 – a clinically relevant biomarker or just nice to have information?

Nadia Harbeck, Torsten Nielson

Cancer Res (2023) 83 (5_Supplement): TC1-3-1.

https://doi.org/10.1158/1538-7445.SABCS22-TC1-3-1

Published: 01 March 2023

View article titled, Abstract TC1-3-1: Ki 67 Ki67 – a clinically relevant biomarker or just nice to have information?

Journal Articles

Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study

Heather McArthur, Javier Cortés, Rebecca Dent, Joyce O’Shaughnessy, Lajos Pusztai, Sherko Küemmel, Theodoros Foukakis, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fatima Cardoso, Carsten Denkert, Yalin Zhu, Yu Ding, Wilbur Pan, Peter Schmid

Cancer Res (2023) 83 (5_Supplement): PD3-01.

https://doi.org/10.1158/1538-7445.SABCS22-PD3-01

Published: 01 March 2023

View article titled, Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study

Journal Articles

Abstract P6-10-06: A preoperative window-of-opportunity study of imlunestrant in estrogen receptor-positive, HER2-negative early breast cancer: Results from the EMBER-2 study

Cancer Res (2023) 83 (5_Supplement): P6-10-06.

https://doi.org/10.1158/1538-7445.SABCS22-P6-10-06

Published: 01 March 2023

View article titled, Abstract P6-10-06: A preoperative window-of-opportunity study of imlunestrant in estrogen receptor-positive, HER2-negative early breast cancer: Results from the EMBER-2 study

Journal Articles

Abstract P2-01-01: Interim analysis (n=200) from ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine

Cancer Res (2023) 83 (5_Supplement): P2-01-01.

https://doi.org/10.1158/1538-7445.SABCS22-P2-01-01

Published: 01 March 2023

View article titled, Abstract P2-01-01: Interim analysis (n=200) from ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine

Journal Articles

Abstract P5-02-03: Combined biomarker analysis for prediction of pathological complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched early breast cancer: Keyriched-1 trial

Cancer Res (2023) 83 (5_Supplement): P5-02-03.

https://doi.org/10.1158/1538-7445.SABCS22-P5-02-03

Published: 01 March 2023

View article titled, Abstract P5-02-03: Combined biomarker analysis for prediction of pathological complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched early breast cancer: Keyriched-1 trial

Journal Articles

Abstract P6-03-08: Trained Artificial Intelligence (AI) for Predicting Treatment Termination Based on Patient Observations in Advanced Breast Cancer

Timo Schinköthe, Ronald Kates, Benedikt Sprecher, Silja Meyer, Christian Horst Tonk, Nadia Harbeck, Annette Schmidt

Cancer Res (2023) 83 (5_Supplement): P6-03-08.

https://doi.org/10.1158/1538-7445.SABCS22-P6-03-08

Published: 01 March 2023

View article titled, Abstract P6-03-08: Trained Artificial Intelligence (AI) for Predicting Treatment Termination Based on Patient Observations in Advanced Breast Cancer

Journal Articles

Abstract OT3-33-01: Prospective, Multi-Center, Artificial Intelligence Study for Early Prediction of Serious Events under Treatment Is Now Open for Recruitment in Breast Cancer - OMCAT Trial in Progress

Timo Schinköthe, Christian Horst Tonk, Ronald Kates, Sherko Küemmel, Fatima Cardoso, Nadia Harbeck, Peter Staib, Annette Schmidt

Cancer Res (2023) 83 (5_Supplement): OT3-33-01.

https://doi.org/10.1158/1538-7445.SABCS22-OT3-33-01

Published: 01 March 2023

View article titled, Abstract OT3-33-01: Prospective, Multi-Center, Artificial Intelligence Study for Early Prediction of Serious Events under Treatment Is Now Open for Recruitment in Breast Cancer - OMCAT Trial in Progress

Journal Articles

Abstract P1-07-03: Unmet needs and future applications of breast cancer multigene signatures in routine clinical practice: results from the European PROCURE Project

Michael Gnant, Anne-Vibeke Lænkholm, Aleix Prat, Judy King, Giuseppe Curigliano, Nadia Harbeck, Frédérique Penault-Llorca, Fatima Cardoso

Cancer Res (2023) 83 (5_Supplement): P1-07-03.

https://doi.org/10.1158/1538-7445.SABCS22-P1-07-03

Published: 01 March 2023

View article titled, Abstract P1-07-03: Unmet needs and future applications of breast cancer multigene signatures in routine clinical practice: results from the European PROCURE Project

Journal Articles

Abstract OT1-01-02: EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET

Komal Jhaveri, Joyce O’Shaughnessy, Fabrice Andre, Matthew P. Goetz, Nadia Harbeck, Miguel Martín, Francois-Clement Bidard, Zachary M. Thomas, Suzanne Young, Roohi Ismail-Khan, Lillian M. Smyth, Michael Gnant

Cancer Res (2023) 83 (5_Supplement): OT1-01-02.

https://doi.org/10.1158/1538-7445.SABCS22-OT1-01-02

Published: 01 March 2023

View article titled, Abstract OT1-01-02: EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET

Journal Articles

Abstract P1-05-36: AI-Based Smartphone App Using a Single-Lead ECG for Automated QTc Diagnostics in Oncology

Timo Schinköthe, Christian Horst Tonk, Nadia Harbeck, Vanda Carmelo, Joana Gomes Feliciano, Rachel Wuerstlein, Sherko Küemmel, Annette Schmidt

Cancer Res (2023) 83 (5_Supplement): P1-05-36.

https://doi.org/10.1158/1538-7445.SABCS22-P1-05-36

Published: 01 March 2023

View article titled, Abstract P1-05-36: AI-Based Smartphone App Using a Single-Lead ECG for Automated QTc Diagnostics in Oncology

Journal Articles

Abstract P2-13-30: First interim analysis from ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor positive (HER2+) early breast cancer observing real-life extended adjuvant treatment with neratinib

Diana Lüftner, Rupert Bartsch, Urs Breitenstein, Marija Balic, Christian Jackisch, Volkmar Müller, Gabriel Rinnerthaler, Marcus Schmidt, Michael Schwitter, Khalil Zaman, Denise Wrobel, Dagmar Guth, Jürgen Terhaag, Matthias Zaiss, Timo Schinköthe, Nadia Harbeck

Cancer Res (2022) 82 (4_Supplement): P2-13-30.

https://doi.org/10.1158/1538-7445.SABCS21-P2-13-30

Published: 15 February 2022

View article titled, Abstract P2-13-30: First interim analysis from ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor positive (HER2+) early breast cancer observing real-life extended adjuvant treatment with neratinib

Journal Articles

Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

Cancer Res (2022) 82 (4_Supplement): GS1-01.

https://doi.org/10.1158/1538-7445.SABCS21-GS1-01

Published: 15 February 2022

View article titled, Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

Journal Articles

Abstract OT2-11-01: EMBER-3: A randomized phase 3 study of LY3484356, a novel, oral selective estrogen receptor degrader vs investigator’s choice of endocrine therapy of either fulvestrant or exemestane, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer previously treated with endocrine-based therapy

Komal Jhaveri, Nadia Harbeck, Philippe Aftimos, Sung-Bae Kim, Xavier Pivot, Cristina Saura, Giuseppe Curigliano, Monica Casalnuovo, Xuejing Aimee Wang, Suzanne R.L. Young, Lillian Smyth, Joyce O'Shaughnessy

Cancer Res (2022) 82 (4_Supplement): OT2-11-01.

https://doi.org/10.1158/1538-7445.SABCS21-OT2-11-01

Published: 15 February 2022

View article titled, Abstract OT2-11-01: EMBER-3: A randomized phase 3 study of LY3484356, a novel, oral selective estrogen receptor degrader vs investigator’s choice of endocrine therapy of either fulvestrant or exemestane, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer previously treated with endocrine-based therapy

NARROW

Abstract P1-11-01: Trastuzumab deruxtecan vs treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04

Abstract P1-02-01: Comparing the efficacy of aromatase inhibitors vs tamoxifen in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and trial-level meta-analysis

Abstract OT2-16-02: Open-label, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer: DESTINY-Breast12

Abstract OT2-03-02: lidERA Breast Cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy in patients with estrogen receptor+, HER2– early breast cancer

Abstract GS1-09: Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes

Abstract HER2-18: HER2-18 Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04

Abstract TC1-3-1: Ki 67 Ki67 – a clinically relevant biomarker or just nice to have information?

Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study

Abstract P6-10-06: A preoperative window-of-opportunity study of imlunestrant in estrogen receptor-positive, HER2-negative early breast cancer: Results from the EMBER-2 study

Abstract P2-01-01: Interim analysis (n=200) from ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine

Abstract P5-02-03: Combined biomarker analysis for prediction of pathological complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched early breast cancer: Keyriched-1 trial

Abstract P6-03-08: Trained Artificial Intelligence (AI) for Predicting Treatment Termination Based on Patient Observations in Advanced Breast Cancer

Abstract OT3-33-01: Prospective, Multi-Center, Artificial Intelligence Study for Early Prediction of Serious Events under Treatment Is Now Open for Recruitment in Breast Cancer - OMCAT Trial in Progress

Abstract P1-07-03: Unmet needs and future applications of breast cancer multigene signatures in routine clinical practice: results from the European PROCURE Project

Abstract OT1-01-02: EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET

Abstract P1-05-36: AI-Based Smartphone App Using a Single-Lead ECG for Automated QTc Diagnostics in Oncology

Abstract P2-13-30: First interim analysis from ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor positive (HER2+) early breast cancer observing real-life extended adjuvant treatment with neratinib

Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only